

Number of Yellow Card adverse reaction reports received from Wales for GLP-1 medicines from 1st January 2024 to date, direct vs indirect reporting

The GLP-1 medications used in this search include Dulaglutide, Exenatide, Liraglutide, Semaglutide and Tirzepatide

Reporter Type	No. of reports
Direct reporter e.g. Health Professional, Patient, or Other (distributor or other organisation)	1,169
Indirect reporter e.g. Pharmaceutical Company	1
Total	1,170

Number of Yellow Card adverse reaction reports received from Wales for GLP-1 medicines from 1st January 2024 to date broken down by seriousness per year

The GLP-1 medications used in this search include Dulaglutide, Exenatide, Liraglutide, Semaglutide and Tirzepatide

Original Case Creation Year	Non-serious	Serious excl. fatal	Fatal
2024	135	95	0
2025	352	385	5
2026	88	108	2
Total	575	588	7

Number of Yellow Card adverse reaction reports received from Wales for GLP-1 medicines from 1st January 2024 to date broken down by seriousness per sex

The GLP-1 medications used in this search include Dulaglutide, Exenatide, Liraglutide, Semaglutide and Tirzepatide

Sex	Non-serious	Serious excl. fatal	Fatal
Male	110	108	0
Female	354	395	6
Sex not reported	111	85	1
Total	575	588	7

Number of Yellow Card adverse reaction reports received from Wales for GLP-1 medicines from 1st January 2024 to date broken down by seriousness per age group

The GLP-1 medications used in this search include Dulaglutide, Exenatide, Liraglutide, Semaglutide and Tirzepatide

Age group	Non-serious	Serious excl. fatal	Fatal
Age 0-17	1	1	0
Age 18-29	29	46	0
Age 30-39	65	99	0
Age 40-49	68	98	2
Age 50-59	69	69	0
Age 60-69	64	61	2
Age 70-79	28	26	0
Age 80+	3	1	0
Age not reported	248	187	3
Total	575	588	7

Number of Yellow Card adverse reaction reports received from Wales for GLP-1 medicines from 1st January 2024 to date broken down by seriousness per brand

The GLP-1 medications used in this search include Dulaglutide, Exenatide, Liraglutide, Semaglutide and Tirzepatide

Brand Name	Non-serious	Serious excl. fatal	Fatal
DULAGLUTIDE	0	1	0
EXENATIDE	0	1	0
LIRAGLUTIDE	0	1	0
MOUNJARO	385	428	6
OZEMPIC	7	7	0
RYBELSUS	31	9	0
SAXENDA	0	2	0
SEMAGLUTIDE	42	34	0
SKINNYQUICK SEMAGLUTIDE PRODUCT	1	0	0
TIRZEPATIDE	30	49	1
TRULICITY	5	1	0
WEGOVY	74	59	0
Total	575	592*	7

*Please note this number may be greater than the total number of cases as one case can include multiple suspect drugs

Number of Yellow Card adverse reaction reports received from Wales for GLP-1 medicines from 1st January 2024 to date broken down by seriousness per system organ class (SOC)

The GLP-1 medications used in this search include Dulaglutide, Exenatide, Liraglutide, Semaglutide and Tirzepatide

System Organ Class	Non-serious	Serious excl. fatal	Fatal
Blood and lymphatic system disorders	0	3	0
Cardiac disorders	8	17	0
Congenital, familial and genetic disorders	1	0	0
Ear and labyrinth disorders	1	4	0
Endocrine disorders	1	8	0
Eye disorders	8	18	0
Gastrointestinal disorders	349	277	0
General disorders and administration site conditions	57	43	1
Hepatobiliary disorders	0	58	2
Immune system disorders	2	6	0
Infections and infestations	14	23	2
Injury, poisoning and procedural complications	6	46	0
Investigations	9	29	0
Metabolism and nutrition disorders	12	31	0
Musculoskeletal and connective tissue disorders	10	33	1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	0	4	0
Nervous system disorders	75	53	0
Pregnancy, puerperium and perinatal conditions	3	4	0
Psychiatric disorders	25	38	0
Renal and urinary disorders	2	15	0
Reproductive system and breast disorders	10	21	0
Respiratory, thoracic and mediastinal disorders	11	10	1
Skin and subcutaneous tissue disorders	67	23	0
Surgical and medical procedures	2	7	0
Vascular disorders	5	19	0
Total	678*	790*	7

*Please note this number may be greater than the total number of cases as one case can include adverse drug reactions from multiple SOCs